Stabilis

Vancomycin hydrochloride



Nombre comercial

Amplobac	Brasil
Anco L IV	Turquía
Celovan	Brasil, India, Marruecos, Venezuela
Dhacocin	Malasia
Edicin	Eslovenia, Polonia, Rumania, Turquía
Estafimac	México
Estavam	México
Imvaco	Chile
Kovan	Chile
Rivervan	Argentina
Tancofeto	Colombia, Malasia
Vacsol	México
Valcidem	México
Vamysin	Bélgica, Luxemburgo
Vanaurus	Colombia, Ecuador
Vanbiotic	Colombia, Ecuador
Vancam	México
Vancobact	Egipto
Vancobiotic	Marruecos
Vancocare	India
Vancocin	Arabia Saudita, Australia, Austria, Canadá, Emiratos Árabes Unidos, Estados Unidos de América, Gran Bretaña, Hungría, India, Irlanda, Luxemburgo, Países Bajos, Polonia, Suecia, Suiza
Vancocina	Brasil, Italia
Vancofar	Marruecos
Vancogen	India
Vancoled	Emiratos Árabes Unidos, India
Vancolon	Arabia Saudita, Egipto, Emiratos Árabes Unidos
Vancomate	India
Vancomax	Argentina, Ecuador, Irán, Marruecos
Vancomicina	Argentina, Chile, Colombia, Ecuador, España, Italia, México, Portugal, Rumania, Túnez
Vancomix	Egipto

Vancomycin	Alemania, Arabia Saudita, Australia, Austria, Canadá, Dinamarca, Egipto, Emiratos Árabes Unidos, Estados Unidos de América, Finlandia, Gran Bretaña, Grecia, Hungría, Irlanda, Islandia, Noruega, Nueva Zelanda, Suecia
Vancomycine	Bélgica, Egipto, Francia, Luxemburgo, Marruecos, Países Bajos, Suiza
Vanconat	India
Vanconor	Marruecos
Vancorin	India, Malasia, Turquía
Vancosan	Alemania, Grecia
Vancoser	India
Vancotek	Turquía
Vancotex	Italia
Vancox	México
Vankomisin	Turquía
Vanlid	India, Malasia, Venezuela
Varedet	Argentina, Colombia, Ecuador, Marruecos
Yestafhal	México
Zengac	Italia

Estabilidad en solucion

		0,005 mg/ml	2-8°C		7			4922
		0,025 mg/ml	4°C		63			1414
		10 mg/ml	-20°C		90			3120
		10 mg/ml	25°C	?	48			3120
		10 mg/ml	4°C	?	8			3120
		2 mg/ml	2-8°C		7			702
		2 mg/ml	25°C		48			702
		5 mg/ml	-10°C		63			430
		5 mg/ml	24°C	?	17			430
		5 mg/ml	5°C		63			430
		2 mg/ml	2-8°C		7			702
		2 mg/ml	25°C		48			702
		25 mg/ml	-20°C	?	90			1871
		5 mg/ml	-10°C		63			430

		5 mg/ml	24°C	?	17				430
		5 mg/ml	5°C		63				430
	Phenol 0.04%	0,005 mg/ml	2-8°C		7				4922
PVC		2 mg/ml	2-8°C		7				702
PVC		2 mg/ml	25°C		48				702
PVC		4 & 5 mg/ml	23°C	?	24				694
PVC		4 & 5 mg/ml	4°C		30				694
PVC		5 mg/ml	22°C		48				1671
PVC		5 mg/ml	24°C	?	17				430
PVC		5 mg/ml	4°C		7				1671
PVC		0,5 & 1 mg/ml	4°C		58				931
PVC		2 mg/ml	2-8°C		7				702
PVC		2 mg/ml	25°C		48				702
PVC		20 & 40 mg/ml	25°C	?	96				654
PVC		20 & 40 mg/ml	5°C	?	30				654
PVC		4 & 5 mg/ml	23°C	?	17				694
PVC		4 & 5 mg/ml	4°C		24				694
PVC		5 mg/ml	22°C		48				1671
PVC		5 mg/ml	24°C	?	17				430
PVC		5 mg/ml	4°C		7				1671
PVC	Δ® P1 1.36	0,025 mg/ml	20°C		28				2370
PVC	Δ® P1 1.36	0,025 mg/ml	37°C		7				2370
PVC	Δ® P1 1.36	0,025 mg/ml	4°C	?	28				2370
PVC	Δ® P1 3.86	0,025 mg/ml	20°C		28				2370
PVC	Δ® P1 3.86	0,025 mg/ml	37°C		5				2370
PVC	Δ® P1 3.86	0,025 mg/ml	4°C	?	28				2370
PVC	EXTRANEAL	0.94 mg/ml	24°C		7				2147
PVC	EXTRANEAL	0.94 mg/ml	37°C		24				2147
PVC	EXTRANEAL	0.94 mg/ml	5°C		7				2147
PVC	EXTRANEAL	1 mg/ml	25°C		14				3888
PVC	EXTRANEAL	1 mg/ml	37°C		4				3888
PVC	EXTRANEAL	1 mg/ml	4°C		14				3888
PE		10 mg/ml	25°C		29				913

PE		10 mg/ml	4°C		84				913
PE		10 mg/ml	25°C		33				913
PE		10 mg/ml	4°C		84				913
PE		10 mg/ml	25°C		33				913
PE		10 mg/ml	4°C		84				913
PE		5 mg/ml	-20°C		105				2034
PE		5 mg/ml	4°C		56				2034
POF		2 mg/ml	2-8°C		7				702
POF		2 mg/ml	25°C		48				702
POF		2 mg/ml	2-8°C		7				702
POF		2 mg/ml	25°C		48				702
EVA		10 mg/ml	23°C		7				1614
EVA		10 mg/ml	4°C		30				1614
PP		0,005 mg/ml	2-8°C		7				4922
PP		10 mg/ml	25°C		47				913
PP		10 mg/ml	4°C		84				913
PP		40 mg/ml	20-25°C		24				4007
PP		0,025 mg/ml	4°C		14				895
PP		10 mg/ml	-20°C		168				2530
PP		10 mg/ml	25°C		62				913
PP		10 mg/ml	4°C		84				913
PP		10 mg/ml	4°C		98				2530
PP		25 mg/ml	23-27°C		24				4373
PP		40 mg/ml	20-25°C		24				4007
PP		40 mg/ml	23-27°C		24				4373
PP		41.67 mg/ml	18-25°C		48				4089
PP		5 mg/ml	25°C	?	48				2173
PP		5 mg/ml	4°C	?	180				2173
PP		10 mg/ml	25°C		55				913
PP		10 mg/ml	4°C		84				913
PP		41.67 mg/ml	18-25°C		48				4089
PP		5 mg/ml	25°C	?	48				2173
PP		5 mg/ml	4°C		24				428

		5 mg/ml	4°C	?	180				2173
		62,5 mg/ml	20-25°C		48				4348
		62,5 >> 83,3 mg/ml	20-25°C		48				4634
		83,3 mg/ml	20-25°C		48				4348
	10	5 mg/ml	4°C		24				428
	15	5 mg/ml	4°C		24				428
	20	5 mg/ml	4°C		24				428
	25	5 mg/ml	4°C		24				428
	30	5 mg/ml	4°C		24				428
	Phenol 0.04%	0,005 mg/ml	2-8°C		7				4922
P I		10 & 20 mg/ml	25°C	?	24				604
P I		10 & 20 mg/ml	4°C		10				604
P I		37,5 mg/ml	37°C		48				4634
P I		10 & 20 mg/ml	25°C	?	24				604
P I		10 & 20 mg/ml	4°C		10				604
P I		37,5 mg/ml	37°C		48				4634

Estabilidad en mezcla

		5 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
		0,025 mg/ml	23°C	?	Heparin sodium : 9,75 UI/ml	85	3958
		2 & 5 mg/ml	37°C		Heparin sodium : 2500 UI/ml Sodium citrate : 22 & 40 mg/ml	72	3327
		0,025 mg/ml	4°C		Heparin sodium : 100 UI/ml	63	1414
		0,025 mg/ml	4°C	?	Heparin sodium : 9,75 UI/ml	85	3958
		5 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
		4.9 mg/ml	25°C	?	Palonosetron hydrochloride : 27 µg/ml	4	2228
	RL	5 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
	0.45	5 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
	Ø	5 mg/ml	25°C	?	Ofloxacin : 2 mg/ml	48	889
PVC		1 mg/ml	23°C		Sodium citrate : 40 mg/ml	72	3951
PVC		3 mg/ml	23°C		Sodium citrate : 40 mg/ml	72	3951

PVC		1 mg/ml	23°C		Aztreonam : 4 mg/ml	31	284
PVC		1 mg/ml	32°C		Aztreonam : 4 mg/ml	7	284
PVC		1 mg/ml	4°C		Aztreonam : 4 mg/ml	31	284
PVC		3 mg/ml	4°C		Sodium citrate : 40 mg/ml	72	3951
PVC		1 mg/ml	4°C		Sodium citrate : 40 mg/ml	72	3951
PVC		1 mg/ml	23°C		Aztreonam : 4 mg/ml	14	284
PVC		1 mg/ml	32°C		Aztreonam : 4 mg/ml	7	284
PVC		1 mg/ml	4°C		Aztreonam : 4 mg/ml	31	284
PVC	Δ® P2 4.25	1 mg/ml	24°C		Ceftazidime : 0,5 mg/ml	24	1416
PVC	Δ® P2 4.25	1 mg/ml	37°C		Ceftazidime : 0,5 mg/ml	12	1416
PVC	Δ® P2 4.25	1 mg/ml	4°C		Ceftazidime : 0,5 mg/ml	24	1416
PVC	Δ® P2 1.5	1 mg/ml	24°C		Ceftazidime : 0,5 mg/ml	24	1416
PVC	Δ® P2 1.5	1 mg/ml	37°C		Ceftazidime : 0,5 mg/ml	12	1416
PVC	Δ® P2 1.5	1 mg/ml	4°C		Ceftazidime : 0,5 mg/ml	24	1416
PVC	EXTRANEAL	1 mg/ml	25°C		Gentamicin sulfate : 0,02 mg/ml	14	3888
PVC	EXTRANEAL	1 mg/ml	37°C		Gentamicin sulfate : 0,02 mg/ml	4	3888
PP		0,1 mg/ml	4°C		Heparin sodium : 5000 UI/ml	28	3956
PP		5 mg/ml	25°C		Paracetamol : 10 mg/ml	4	3571
PP		0,025 mg/ml	4°C		Heparin sodium : 100 UI/ml	14	895
		1 mg/ml	37°C		Sodium citrate : 40 mg/ml	72	3951
		3 mg/ml	37°C		Sodium citrate : 40 mg/ml	72	3951
		0,5 mg/ml	25°C		Famotidine : 0,2 mg/ml	14	1748
		0,5 mg/ml	4°C		Famotidine : 0,2 mg/ml	14	1748

Factores que influyen sobre la estabilidad

	37°C				1167
	[>62,5 mg/m				4348
	80 mg/ml				4128

Compatibilidades

		Vancomycin hydrochloride : 5 mg/ml Aciclovir sodium : 5 mg/ml		336
		Vancomycin hydrochloride : 10 mg/ml Allopurinol sodium : 3 mg/ml		307
		Vancomycin hydrochloride : 5 mg/ml Alprostadil : 15 µg/ml		3201
		Vancomycin hydrochloride : 10 mg/ml Amifostine : 10 mg/ml		3
		Vancomycin hydrochloride : 10 mg/ml Amikacin sulfate : 15 mg/ml		3385
		Vancomycin hydrochloride Aminophylline		3588
		Vancomycin hydrochloride : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Vancomycin hydrochloride : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Vancomycin hydrochloride : 31,3 mg/ml Amiodarone hydrochloride : 9 mg/ml		4698
		Vancomycin hydrochloride : 10 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Vancomycin hydrochloride : 4 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Vancomycin hydrochloride Amobarbital sodium		3588
		Vancomycin hydrochloride : 31.25 mg/ml Amoxicillin sodium : 20.83 mg/ml		4254
		Vancomycin hydrochloride : 50 mg/ml Amoxicillin sodium : 20 mg/ml		4957
		Vancomycin hydrochloride : 50 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Vancomycin hydrochloride : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Vancomycin hydrochloride : 10 & 62.5 & 83.3 mg/ml Amphotericin B liposomale : 1.16 mg/ml		4254
		Vancomycin hydrochloride : 2 mg/ml Ampicillin sodium : 1 >> 250 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Ampicillin sodium : 1 >> 50 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Ampicillin sodium : 250 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Ampicillin sodium - sulbactam sodium : 1/0.5 >> 50/25 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Ampicillin sodium - sulbactam sodium : 1/0.5 >> 250/125 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Ampicillin sodium - sulbactam sodium : 250-125 mg/ml		1674
		Vancomycin hydrochloride : 10 mg/ml Amsacrine : 1 mg/ml		253

		Vancomycin hydrochloride : 10 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Vancomycin hydrochloride Ascorbic acid		3588
		Vancomycin hydrochloride : 5 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Vancomycin hydrochloride : 1 mg/ml Aztreonam : 4 mg/ml		284
		Vancomycin hydrochloride : 10 mg/ml Aztreonam : 40 mg/ml		284
		Vancomycin hydrochloride : 66.67 mg/ml Aztreonam : 200 mg/ml		94
		Vancomycin hydrochloride : 10 mg/ml Aztreonam : 40 mg/ml		99
		Vancomycin hydrochloride Bivalirudin		3539
		Vancomycin hydrochloride : 10 mg/ml Caffeine : 10 mg/ml		4837
		Vancomycin hydrochloride		1671
		Vancomycin hydrochloride : 10 mg/ml Aztreonam : 40 mg/ml		284
		Vancomycin hydrochloride : 1 mg/ml Aztreonam : 4 mg/ml		284
		Vancomycin hydrochloride : 10 mg/ml Bivalirudin : 5 mg/ml		1713
		Vancomycin hydrochloride : 2 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Vancomycin hydrochloride : 50 mg/ml Caffeine : 10 mg/ml	∅	3964
		Vancomycin hydrochloride : 10 mg/ml Caffeine citrate : 20 mg/ml		4837
		Vancomycin hydrochloride : 10 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Vancomycin hydrochloride : 250 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Vancomycin hydrochloride : 20 mg/ml Cefazolin sodium : 10 >> 200 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefazolin sodium : 1 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Cefazolin sodium : 50 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Cefazolin sodium : 1 ; 10 & 200 mg/ml		1674
		Vancomycin hydrochloride : 10 mg/ml Cefepime dihydrochloride : 200 mg/ml		3385
		Vancomycin hydrochloride : 4 mg/ml Cefepime dihydrochloride : 20 mg/ml		3542
		Vancomycin hydrochloride : 30 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Vancomycin hydrochloride : 31,25 mg/ml Cefepime dihydrochloride : 125 mg/ml		4957
		Vancomycin hydrochloride : 10 mg/ml		3948

		Vancomycin hydrochloride : 5 mg/ml		966
		Vancomycin hydrochloride : 5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Vancomycin hydrochloride : 10 mg/ml		1415
		Vancomycin hydrochloride : 0.0974 >> 1.333 mg/ml		1868
		Vancomycin hydrochloride : 10 mg/ml Cefepime dihydrochloride : 83.33 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml		4924
		Vancomycin hydrochloride		3985
		Vancomycin hydrochloride Cefepime dihydrochloride		3548
		Vancomycin hydrochloride : 5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Vancomycin hydrochloride : 4 & 50 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Vancomycin hydrochloride : 20 mg/ml Cefonicid sodium : 10 >> 225 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Cefonicid sodium : 1 >> 225 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefonicid sodium : 1 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefotaxime sodium : 50 & 200 mg/ml		1674
		Vancomycin hydrochloride : 0.5 & 1 mg/ml		895
		Vancomycin hydrochloride : 5 mg/ml		316
		Vancomycin hydrochloride : 50 mg/ml		999
		Vancomycin hydrochloride : 10 mg/ml		3948
		Vancomycin hydrochloride : 10 mg/ml		939
		Vancomycin hydrochloride : 10 mg/ml		301
		Vancomycin hydrochloride : 5 & 12,5 mg/ml Cefotaxime sodium : 100 mg/ml		260
		Vancomycin hydrochloride : 25 & 30 mg/ml Cefotaxime sodium : 100 mg/ml		260
		Vancomycin hydrochloride : 2 mg/ml Cefotaxime sodium : 1 >> 200 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefotaxime sodium : 1 & 10 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefoxitin sodium : 1 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefoxitin sodium : 50 & 180 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Cefoxitin sodium : 1 >> 180 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefoxitin sodium : 10 mg/ml		1674

		Vancomycin hydrochloride : 5 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Vancomycin hydrochloride : 5 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Vancomycin hydrochloride : 5 mg/ml Cefpirome sulfate : 50 mg/ml	0.45	280
		Vancomycin hydrochloride : 5 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Vancomycin hydrochloride : 5 mg/ml Ceftazidime : 5 mg/ml	Δ® 1.5	3101
		Vancomycin hydrochloride : 1 mg/ml Ceftazidime : 0.5 mg/ml	Δ® P2 4.25	1416
		Vancomycin hydrochloride : 10 mg/ml Ceftazidime : 125 mg/ml		3385
		Vancomycin hydrochloride : 30 mg/ml Ceftazidime : 125 mg/ml		2141
		Vancomycin hydrochloride : 10 mg/ml Ceftazidime : 40 mg/ml		1399
		Vancomycin hydrochloride : 20 mg/ml Ceftazidime : 1 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Ceftazidime : 1 >> 200 mg/ml		1674
		Vancomycin hydrochloride : 5 mg/ml Ceftazidime : 5 mg/ml	Δ® 2.5	3101
		Vancomycin hydrochloride : 5 mg/ml Ceftazidime : 5 mg/ml	Δ® 4.25	3101
		Vancomycin hydrochloride : 30 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Vancomycin hydrochloride		1671
		Vancomycin hydrochloride : 5 mg/ml		4488
		Vancomycin hydrochloride : 20 mg/ml Ceftazidime : 10 >> 200 mg/ml		1674
		Vancomycin hydrochloride : 10 & 100 mg/ml Ceftazidime : 22 & 200 mg/ml		1877
		Vancomycin hydrochloride Ceftazidime		3543
		Vancomycin hydrochloride Ceftazidime		3883
		Vancomycin hydrochloride : 10 mg/ml Ceftazidime : 20 mg/ml		1959
		Vancomycin hydrochloride : 5 mg/ml Ceftazidime Avibactam : 8 mg/ml		3984
		Vancomycin hydrochloride : 10 mg/ml Ceftazidime Avibactam : 8 & 20 mg/ml		3984
		Vancomycin hydrochloride : 15 mg/ml Ceftazidime Avibactam : 8 >> 40 mg/ml		3984
		Vancomycin hydrochloride : 50 mg/ml	RL	4603
		Vancomycin hydrochloride : 5 mg/ml		4440
		Vancomycin hydrochloride : 5 mg/ml Ceftazidime Avibactam : 20 & 40 mg/ml		3984

		Vancomycin hydrochloride : 10 mg/ml Ceftazidime Avibactam : 40 mg/ml		3984
		Vancomycin hydrochloride : 20 mg/ml Ceftizoxime sodium : 280 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Ceftizoxime sodium : 1 >> 280 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Ceftizoxime sodium : 1 >> 50 mg/ml		1674
		Vancomycin hydrochloride : 15 mg/ml Ceftolozane / tazobactam : 15 mg/ml		3984
		Vancomycin hydrochloride : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Vancomycin hydrochloride : 5 & 10 mg/ml Ceftolozane / tazobactam : 15 mg/ml		3984
		Vancomycin hydrochloride : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Vancomycin hydrochloride : 2 mg/ml Ceftriaxone disodium : 1 >> 250 mg/ml		1674
		Vancomycin hydrochloride Ceftriaxone disodium		3523
		Vancomycin hydrochloride : 20 mg/ml Ceftriaxone disodium : 1 >> 250 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Ceftriaxone disodium : 100 mg/ml		95
		Vancomycin hydrochloride : 20 mg/ml Cefuroxime sodium : 1 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Cefuroxime sodium : 10 >> 150 mg/ml		1674
		Vancomycin hydrochloride : 2 mg/ml Cefuroxime sodium : 1 >> 150 mg/ml		1674
		Vancomycin hydrochloride Chloramphenicol sodium succinate		3588
		Vancomycin hydrochloride Chlorothiazide sodium		3588
		Vancomycin hydrochloride : 5 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Vancomycin hydrochloride : 10 mg/ml Ciprofloxacin lactate : 2 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Vancomycin hydrochloride : 50 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Vancomycin hydrochloride : > 2 mg/ml Cloxacillin sodium : > 1.25 mg/ml		3557
		Vancomycin hydrochloride : < 2 mg/ml Cloxacillin sodium : < 1.25 mg/ml		3557
		Vancomycin hydrochloride : 10 mg/ml Colistin mesilate sodium : 1.5 mg/ml		3997
		Vancomycin hydrochloride Daunorubicin/cytarabine liposomale		4354
		Vancomycin hydrochloride Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654

		Vancomycin hydrochloride : 10.4 mg/ml Defibrotide : 8 mg/ml	▲	3728
		Vancomycin hydrochloride Dexamethasone sodium phosphate		3668
		Vancomycin hydrochloride Dexamethasone sodium phosphate		3588
		Vancomycin hydrochloride : 10 mg/ml Dexmedetomidine : 4 µg/ml	▲	1712
		Vancomycin hydrochloride : 5 & 50 mg/ml Diltiazem hydrochloride : 5 mg/ml	▲	198
		Vancomycin hydrochloride Dimenhydrinate		2087
		Vancomycin hydrochloride : 10 mg/ml Dobutamine hydrochloride : 1 mg/ml	◆	3385
		Vancomycin hydrochloride : 10 mg/ml Docetaxel : 0.9 mg/ml	◆	1754
		Vancomycin hydrochloride : 10 mg/ml Dopamine hydrochloride : 0.4 mg/ml	◆	3385
		Vancomycin hydrochloride : 10 mg/ml Doripenem : 5 mg/ml	◆	2262
		Vancomycin hydrochloride : 10 mg/ml Doripenem : 5 mg/ml	▲	2262
		Vancomycin hydrochloride : 5 mg/ml Doxapram hydrochloride : 2 mg/ml	◆	1802
		Vancomycin hydrochloride : 10 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	◆	251
		Vancomycin hydrochloride : 5 mg/ml Enalaprilate : 0.05 mg/ml	▲	1315
		Vancomycin hydrochloride : 10 mg/ml Epinephrine hydrochloride : 50 µg/ml	◆	3385
		Vancomycin hydrochloride : 5 mg/ml Eravacycline : 0,6 mg/ml	▲	4434
		Vancomycin hydrochloride : 10 mg/ml Erythromycin lactobionate : 5 mg/ml	◆	3385
		Vancomycin hydrochloride : 5 mg/ml Esmolol hydrochloride : 10 mg/ml	◆	384
		Vancomycin hydrochloride : 10 mg/ml Etoposide phosphate : 5 mg/ml	◆	1410
		Vancomycin hydrochloride : 5 mg/ml Famotidine : 0,2 mg/ml	◆	1748
		Vancomycin hydrochloride : 10 mg/ml Fenoldopam mesylate : 80 µg/ml	▲	1803
		Vancomycin hydrochloride : 5 mg/ml Fentanyl citrate : 50 µg/ml	◆	63
		Vancomycin hydrochloride : 10 mg/ml Filgrastim : 30 µg/ml	◆	244
		Vancomycin hydrochloride : 10 mg/ml Flucloxacillin sodium : 250 mg/ml	◆	3385
		Vancomycin hydrochloride : 10 mg/ml Fluconazole : 2 mg/ml	◆	3385
		Vancomycin hydrochloride : 20 mg/ml Fluconazole : 2 mg/ml	▲	496

		Vancomycin hydrochloride : 10 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Vancomycin hydrochloride : 20 mg/ml Foscarnet sodium : 24 mg/ml		73
		Vancomycin hydrochloride : 15 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Vancomycin hydrochloride : 10 mg/ml Foscarnet sodium : 24 mg/ml		132
		Vancomycin hydrochloride : 15 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Vancomycin hydrochloride Foscarnet sodium		3662
		Vancomycin hydrochloride : 5 mg/ml Fosfomycin : 30 mg/ml		4055
		Vancomycin hydrochloride : 5 mg/ml Fosfomycin : 30 mg/ml		4055
		Vancomycin hydrochloride : 10 mg/ml Furosemide : 10 mg/ml		3385
		Vancomycin hydrochloride : 5 mg/ml Gallium nitrate : 1 mg/ml		91
		Vancomycin hydrochloride : 5 mg/ml Gelatin		3485
		Vancomycin hydrochloride : 10 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Vancomycin hydrochloride : 10 mg/ml Gentamicin sulfate : 6 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Vancomycin hydrochloride : 2 mg/ml Heparin sodium : 10 UI/ml		2037
		Vancomycin hydrochloride : 6,9 >> 14,3 mg/ml Heparin sodium : 0,5 >> 14,3 UI/ml	Δ® P1 ◆4.25	2375
		Vancomycin hydrochloride : 10 mg/ml Heparin sodium : 100 UI/ml		132
		Vancomycin hydrochloride : 2.5 mg/ml Heparin sodium : 5000 UI/ml		2037
		Vancomycin hydrochloride : 0,015 >> 6,8 mg/ml Heparin sodium : 0,5 >> 14,3 UI/ml	Δ® P2 ◆2.5	2375
		Vancomycin hydrochloride : 0,015 >> 6,8 mg/ml Heparin sodium : 0,5 >> 14,3 UI/ml	Δ® P1 ◆4.25	2375
		Vancomycin hydrochloride Heparin sodium		3588
		Vancomycin hydrochloride Heparin sodium		3540
		Vancomycin hydrochloride : 6,9 >> 14,3 mg/ml Heparin sodium : 0,5 >> 14,3 UI/ml	Δ® P2 ◆2.5	2375
		Vancomycin hydrochloride : 0.025 mg/ml Heparin sodium : 100 UI/ml		1414
		Vancomycin hydrochloride : 6.6 mg/ml Heparin sodium : 50 UI/ml		317
		Vancomycin hydrochloride : 0.025 mg/ml Heparin sodium : 10 UI/ml		3125

		Vancomycin hydrochloride : 0.025 mg/ml Heparin sodium : 100 UI/ml		895
		Vancomycin hydrochloride : 5 mg/ml Hetastarch : 60 mg/ml		3485
		Vancomycin hydrochloride : 10 mg/ml Hetastarch : 60 mg/ml		1721
		Vancomycin hydrochloride : 5 mg/ml Human albumin : 45 mg/ml		3485
		Vancomycin hydrochloride Hydrocortisone sodium succinate		3588
		Vancomycin hydrochloride : 4 mg/ml Hydromorphone hydrochloride : 2 mg/ml		2335
		Vancomycin hydrochloride : 5 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Vancomycin hydrochloride : 50 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Vancomycin hydrochloride : 4 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Vancomycin hydrochloride : 4 mg/ml Insulin : 0.2 UI/ml		129
		Vancomycin hydrochloride : 10 mg/ml Insulin : 100 UI/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Insulin aspart : 1 UI/ml		1508
		Vancomycin hydrochloride : 10 mg/ml Insulin aspart : 1 UI/ml		1508
		Vancomycin hydrochloride : 5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Vancomycin hydrochloride : 5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Vancomycin hydrochloride : 10 mg/ml Isosorbide dinitrate : 0.2 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Ketamine hydrochloride : 10 mg/ml		3385
		Vancomycin hydrochloride : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Vancomycin hydrochloride : 5 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Vancomycin hydrochloride : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Vancomycin hydrochloride : 5 mg/ml Levetiracetam : 5 mg/ml		4569
		Vancomycin hydrochloride : 50 mg/ml Levofloxacine : 5 mg/ml		1072
		Vancomycin hydrochloride : 10 mg/ml Linezolid : 2 mg/ml		1925
		Vancomycin hydrochloride : 5 mg/ml Lorazepam : 0.33 mg/ml		186
		Vancomycin hydrochloride : 5 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Vancomycin hydrochloride : 10 mg/ml Melphalan : 0.1 mg/ml		169

		Vancomycin hydrochloride : 50 mg/ml Meropenem : 50 mg/ml		4319
		Vancomycin hydrochloride : 1 mg/ml Meropenem : 1 & 20 mg/ml		266
		Vancomycin hydrochloride : 5 mg/ml Meropenem : 1 & 50 mg/ml		266
		Vancomycin hydrochloride : 5 mg/ml Methotrexate sodium : 30 mg/ml		150
		Vancomycin hydrochloride : 5 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Vancomycin hydrochloride : 5 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Vancomycin hydrochloride : 10 mg/ml Midazolam hydrochloride : 5 mg/ml		3385
		Vancomycin hydrochloride : 5 mg/ml Morphine sulfate : 1 mg/ml		405
		Vancomycin hydrochloride : 10 mg/ml Moxifloxacin : 1.6 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Mycophenolate mofetil : 5,9 mg/ml		2192
		Vancomycin hydrochloride : 10 mg/ml N-acetylcysteine : 100 mg/ml		3385
		Vancomycin hydrochloride : 2 mg/ml Nafcillin sodium : 10 >> 250 mg/ml		1674
		Vancomycin hydrochloride : 2 & 20 mg/ml Nafcillin sodium : 1 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Nafcillin sodium : 10 >> 250 mg/ml		1674
		Vancomycin hydrochloride : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Vancomycin hydrochloride : 31.25 mg/ml Nefopam : 0.16 mg/ml		4254
		Vancomycin hydrochloride : 31.25 mg/ml Nefopam : 0.16 mg/ml		4254
		Vancomycin hydrochloride : 5 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Vancomycin hydrochloride : 10 mg/ml Nicardipine hydrochloride : 1 mg/ml		3385
		Vancomycin hydrochloride : 5 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Vancomycin hydrochloride : 5 mg/ml Ofloxacin : 2 mg/ml		889
		Vancomycin hydrochloride : 10 mg/ml Omeprazole sodium : 4 mg/ml		264
		Vancomycin hydrochloride : 10 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Vancomycin hydrochloride : 10 mg/ml Oxacillin sodium : 20 mg/ml		3813
		Vancomycin hydrochloride : 12 mg/ml Oxycodone hydrochloride : 1 mg/ml		4842
		Vancomycin hydrochloride : 10 mg/ml Paclitaxel : 1.2 mg/ml		85

		Vancomycin hydrochloride : 5 mg/ml Palonosetron hydrochloride : 50 µg/ml		2228
		Vancomycin hydrochloride : 5 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Vancomycin hydrochloride Pantoprazole sodium		2090
		Vancomycin hydrochloride : 40 mg/ml Pantoprazole sodium : 8 mg/ml		2139
		Vancomycin hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml	∅	3571
		Vancomycin hydrochloride : 50 mg/ml Paracetamol : 10 mg/ml		4742
		Vancomycin hydrochloride : 10 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Vancomycin hydrochloride Penicillin G potassium		3588
		Vancomycin hydrochloride : 10 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Vancomycin hydrochloride : 5 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Vancomycin hydrochloride : 4 mg/ml Phenytoin sodium : 5 mg/ml		3421
		Vancomycin hydrochloride Phenytoin sodium		3588
		Vancomycin hydrochloride : 10 mg/ml Phenytoin sodium : 50 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Vancomycin hydrochloride : 2 mg/ml Piperacillin sodium : 1 >> 200 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Piperacillin sodium : 1 mg/ml		1674
		Vancomycin hydrochloride : 20 mg/ml Piperacillin sodium : 10 >> 250 mg/ml		1674
		Vancomycin hydrochloride : 10 mg/ml Piperacillin sodium / tazobactam : 100/12,5 mg/ml		3365
		Vancomycin hydrochloride : 10 mg/ml Piperacillin sodium / tazobactam : 200 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Piperacillin sodium / tazobactam : 16 >> 30 mg/ml		2475
		Vancomycin hydrochloride : 5 mg/ml	Normo Sol®	4655
		Vancomycin hydrochloride : 20 mg/ml Piperacillin sodium / tazobactam : 1/0.125 mg/ml		1674
		Vancomycin hydrochloride : 10 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Vancomycin hydrochloride : 20 mg/ml Piperacillin sodium / tazobactam : 10/1.25 >> 200/25 mg/ml		1674
		Vancomycin hydrochloride : 10 mg/ml Piperacillin sodium / tazobactam : 112,5 mg/ml		3428
		Vancomycin hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 80 >> 100 mg/ml		2475

		Vancomycin hydrochloride : 8 mg/ml Piperacillin sodium / tazobactam : 16 >> 100 mg/ml	◆	2475
		Vancomycin hydrochloride : 8 mg/ml Piperacillin sodium / tazobactam : 33.75 >> 67.5 mg/ml	▲	3841
		Vancomycin hydrochloride : 10 & 15 mg/ml Piperacillin sodium / tazobactam : 28 mg/ml	◆	3984
		Vancomycin hydrochloride : 5 mg/ml Piperacillin sodium / tazobactam : 67,5 mg/ml	◆	3960
		Vancomycin hydrochloride : 4 >> 7 mg/ml Piperacillin sodium / tazobactam : 33.75 >> 90 mg/ml	▲	3841
		Vancomycin hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 16 >> 40 mg/ml	◆	2475
		Vancomycin hydrochloride : 5 mg/ml Piperacillin sodium / tazobactam : 28 mg/ml	◆	3984
		Vancomycin hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	▲	3421
		Vancomycin hydrochloride : 4 mg/ml Piperacillin sodium / tazobactam : 30/3,75 mg/ml	▲	3421
		Vancomycin hydrochloride : 2 mg/ml Piperacillin sodium / tazobactam : 1/0.125 >> 200/25 mg/ml	◆	1674
		Vancomycin hydrochloride : 8 mg/ml Piperacillin sodium / tazobactam : 80 & 90 mg/ml	▲	3841
		Vancomycin hydrochloride : 5 mg/ml Piperacillin sodium / tazobactam : 16 >> 100 mg/ml	▲	2475
		Vancomycin hydrochloride : 2 mg/ml Piperacillin sodium / tazobactam : 16 >> 100 mg/ml	▲	2475
		Vancomycin hydrochloride : 10 mg/ml Piperacillin sodium / tazobactam : 40 >> 100 mg/ml	▲	2475
		Vancomycin hydrochloride : >8 mg/ml Piperacillin sodium / tazobactam	▲	3841
		Vancomycin hydrochloride : 10 mg/ml Piritramide : 2 mg/ml	◆	3385
		Vancomycin hydrochloride : 5 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
		Vancomycin hydrochloride Posaconazole		4380
		Vancomycin hydrochloride : 10 mg/ml Propofol : 1 mg/ml	◆	3385
		Vancomycin hydrochloride : 50 mg/ml Propofol		4524
		Vancomycin hydrochloride : 4 mg/ml Propofol		660
		Vancomycin hydrochloride : 10 mg/ml Propofol : 10 mg/ml	∅	300
		Vancomycin hydrochloride Pyridoxine hydrochloride		3588
		Vancomycin hydrochloride : 10 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
		Vancomycin hydrochloride Rocuronium bromide		3564
		Vancomycin hydrochloride : 50 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216

		Vancomycin hydrochloride : 20 mg/ml Sargramostim : 15 µg/ml		891
		Vancomycin hydrochloride : 10 mg/ml Sargramostim : 10 µg/ml		335
		Vancomycin hydrochloride : 20 mg/ml Sargramostim : 6 µg/ml		891
		Vancomycin hydrochloride : 10 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
		Vancomycin hydrochloride : 5 mg/ml Sodium bicarbonate : 40 mg/ml		3122
		Vancomycin hydrochloride : 10 mg/ml Sodium bicarbonate : 40 mg/ml		3122
		Vancomycin hydrochloride : 1 & 3 mg/ml Sodium citrate : 40 mg/ml		3951
		Vancomycin hydrochloride : 5 & 10 mg/ml Sodium citrate : 40 mg/ml		4027
		Vancomycin hydrochloride : 20 mg/ml Sodium citrate : 40 mg/ml		3122
		Vancomycin hydrochloride : 10 mg/ml Sufentanil citrate : 0.005 mg/ml		3385
		Vancomycin hydrochloride : 5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Vancomycin hydrochloride : 5 mg/ml Tacrolimus : 1000 µg/ml		479
		Vancomycin hydrochloride : 5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Vancomycin hydrochloride : 30 mg/ml Temocilline : 83.33 mg/ml		2231
		Vancomycin hydrochloride : 10 mg/ml Temocilline : 100 mg/ml		3385
		Vancomycin hydrochloride Temocilline		4470
		Vancomycin hydrochloride : 10 mg/ml Teniposide : 0.1 mg/ml		905
		Vancomycin hydrochloride : 6.6 mg/ml Theophylline : 4 mg/ml		317
		Vancomycin hydrochloride : 10 mg/ml Theophylline : 20 mg/ml		3385
		Vancomycin hydrochloride Theophylline		5054
		Vancomycin hydrochloride Thiamine hydrochloride		3588
		Vancomycin hydrochloride : 50 mg/ml Thiopental sodium : 25 mg/ml		3767
		Vancomycin hydrochloride : 10 mg/ml Thiotepa : 1 mg/ml		249
		Vancomycin hydrochloride : 2 mg/ml Ticarcillin / clavulanic acid : 1/0.034 >> 200/6.7 mg/ml		1674
		Vancomycin hydrochloride Ticarcillin / clavulanic acid		1649
		Vancomycin hydrochloride : 20 mg/ml Ticarcillin / clavulanic acid : 1/0.034 >> 200/6.7 mg/ml		1674

		Vancomycin hydrochloride : 10 mg/ml Tobramycin sulfate : 6 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Urapidil : 5 mg/ml		3385
		Vancomycin hydrochloride : 10 mg/ml Valproic acid : 100 mg/ml		3385
		Vancomycin hydrochloride : 5 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Vancomycin hydrochloride : 1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Vancomycin hydrochloride : 1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Vancomycin hydrochloride : 10 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Vancomycin hydrochloride : 4 mg/ml Warfarin sodium : 2 mg/ml		315
		Vancomycin hydrochloride : 10 mg/ml Warfarin sodium : 0.1 mg/ml		552
		Vancomycin hydrochloride : 10 mg/ml Warfarin sodium : 2 mg/ml		552
		Vancomycin hydrochloride : 10 mg/ml Warfarin sodium : 2 mg/ml		552
		Vancomycin hydrochloride : 10 mg/ml Warfarin sodium : 0.1 mg/ml		552
		Vancomycin hydrochloride Warfarin sodium		3588
		Vancomycin hydrochloride : 15 mg/ml Zidovudine : 4 mg/ml		337

método de inyección



Bibliografía

	Tipo	Publicación
3	periódico	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	periódico	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	periódico	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	periódico	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.

81	periódico	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	periódico	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	periódico	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	periódico	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	periódico	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
94	periódico	Chandler SW, Folstad J, Trissel LA. Aztreonam-vancomycin incompatibility. Am J Hosp Pharm 1990 ; 47: 1970.
95	periódico	Pritts D, Hancock D. Incompatibility of ceftriaxone with vancomycin. Am J Hosp Pharm 1991 ; 48: 77.
99	periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	periódico	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
132	periódico	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	periódico	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	periódico	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	periódico	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	periódico	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	periódico	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.

249	periódico	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	periódico	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
260	periódico	Szof C, Walker PC. Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration. Am J Hosp Pharm 1993 ; 50: 2054, 2057.
264	periódico	Leboucher G, Charpiat B. Incompatibilité physico-chimique entre l'oméprazole et la vancomycine. Pharm Hosp Fr 1997 ; 121: 124.
266	periódico	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
280	periódico	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
284	periódico	Trissel LA, Xu QA, Martinez JF. Compatibility and stability of aztreonam and vancomycin hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 2560-2564.
299	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	periódico	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	periódico	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	periódico	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	periódico	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	periódico	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	periódico	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.

335	periódico	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	periódico	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	periódico	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
384	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	periódico	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
402	periódico	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
405	periódico	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
428	periódico	Nahata MC, Miller MA, Durrell DE. Stability of vancomycin hydrochloride in various concentrations of dextrose injection. Am J Hosp Pharm 1987 ; 44: 802-804.
430	periódico	Das Gupta V, Stewart KR, Nohria S. Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm 1986 ; 43: 1729-1731.
479	periódico	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	periódico	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	periódico	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	periódico	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
552	periódico	Martinez JF, Trissel LA, Gilbert DL. Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions. Int J Pharm Compound 1997 ; 1: 356-358.
604	Laboratorio	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998

654	periódico	Allen LV. Stability of vancomycin hydrochloride in Medication Cassette* reservoirs. Int J Pharm Compound 1997 ; 1: 123-124.
660	periódico	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
694	periódico	Walker SE, Birkhans B. Stability of intravenous vancomycin. Can J Hosp Pharm 1988 ; 41: 233-238, 242.
702	periódico	Biellmann-Berlaud V, Willemin JC. Stability of vancomycin in polyolefine or PVC bags and glass vials. J Pharm Clin 1998 ; 17: 145-148.
889	periódico	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
891	periódico	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
895	periódico	Yao JDC, Arkin CF, Karchmer AW. Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. JPEN 1992 ; 16: 268-274.
905	periódico	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
913	periódico	Wood MJ, Lund R, Beavan M. Stability of vancomycin in plastic syringes measured by high-performance liquid chromatography. J Clin Pharm Ther 1995 ; 20: 319-325.
921	periódico	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
931	periódico	Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. Long-term stability of vancomycin hydrochloride in intravenous infusions. J Clin Pharm Ther 1997 ; 22: 353-356.
939	periódico	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
966	periódico	Martins AM, McDougal A, Hamilton D, Igwemezie L, McErlane K. In vitro assessment of vancomycin HCl compatibility after coinfusion with a specialized amino acid formulation. JPEN 1991 ; 15: 536-539.
999	periódico	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1047	periódico	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	periódico	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.

1072	periódico	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	periódico	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1167	periódico	Grennberg RN, Saeed AM, Kennedy DJ, McMillian R. Instability of vancomycin in infusaid drug pump model 100. Antimicrob Agents Chemother 1987 ; 31: 610-611.
1201	periódico	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1399	periódico	Cairns CJ, Robertson J. Incompatibility of ceftazidime and vancomycin. Pharm J 1987 ; 238: 577.
1410	periódico	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1414	periódico	Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J. Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml. J Pharm Technol 1999 ; 15: 13-17.
1415	periódico	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1416	periódico	Stamatakis MK, Leader G, Tracy TS. Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions. Am J Health-Syst Pharm 1999 ; 56: 246-248.
1423	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1508	periódico	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	periódico	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1614	periódico	Trissel LA, Xu QA, Zhang Y, Saenz CA, Ingram DS. Stability of ciprofloxacin and vancomycin hydrochloride in autodose infusion system bags. Hosp Pharm 2001 ; 36: 1170-1173.
1625	periódico	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1649	periódico	Gilbar P, McAllan Z. Ticarcillin-potassium clavulanate and vancomycin incompatibility. Aust J Hosp Pharm 1997 ; 27: 470.

1671	periódico	Khalfi F, Dine T, Gressier B, Luyckx M, Brunet C, Ballester L, Goudaliez F, Cazin M, Cazin JC. Compatibility and stability of vancomycin hydrochloride with PVC infusion material in various conditions using stability-indicating high-performance liquid chromatographic assay. Int J Pharm 1996 ; 139: 243-247.
1674	periódico	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	periódico	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	periódico	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	periódico	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1748	periódico	Wang DP, Wang MT, Wong CY, Lee DKT. Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection. Int J Pharm Compound 1997 ; 1: 354-355.
1754	periódico	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	periódico	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1802	periódico	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	periódico	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1868	periódico	Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1871	periódico	Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J. Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions. Int J Pharm 2002 ; 234: 205-212.
1877	periódico	Lifshitz T, Lapid-Gortzak R, Finkelman Y, Klemperer I. Vancomycin and ceftazidime incompatibility upon vitreal injection. Br Ophtalmol 2000 ; 84: 117.
1925	periódico	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	periódico	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1959	periódico	Mac Lellan C, Papadopoulos A. Precipitate formation after subconjonctival administration of ceftazidime and vancomycin. Hosp Pharm 2005 ; 40, 2: 154-155.

1982	periódico	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2034	periódico	Rodenbach MP, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Effect of freezing, long-term storage and microwave thawing on the stability of vancomycin hydrochloride in 5% dextrose infusions. EJHP Science 2005 ; 11, 5: 111-113.
2037	periódico	Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions ... J Antimicrob Chemother 2005 ; 56: 951-953.
2087	periódico	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	periódico	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	periódico	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2139	periódico	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug's administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2141	periódico	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2147	periódico	Nornoo AO, Elwell RJ. Stability of vancomycin in icodextrin peritoneal dialysis solution. Ann Pharmacotherapy 2006 ; 40, 11: 1950-1954.
2173	periódico	Grioffiths W, Favet J, Ing H, Sadeghipour F, Bonnabry P. Chemical stability and microbiological potency of intravenous vancomycin hydrochloride syringes for use in the neonatal intensive care. EJHP Science 2006 ; 12, 6: 135-139.
2192	periódico	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2228	periódico	Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173.
2231	periódico	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	periódico	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	periódico	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.

2262	periódico	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2335	periódico	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2370	periódico	Mawhinney WM, Adair CG, Gorman SP, McClurg B. Stability of vancomycin hydrochloride in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 137 - 139.
2375	periódico	Strong DK, Ho W, Nairn JG. Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions Am J Hosp Pharm 1989 ; 46: 1832 - 1833.
2475	periódico	Wade J, Cooper M, Ragan R. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam Hosp Pharm 2015 ; 50: 376-379.
2530	periódico	Bartoll A, Bellés Medall M, Peñarrocha J, Escrig L, Clemente R, Azuara J. Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes. Int J Pharm Compound 2022 ;26,4:330-335
3012	periódico	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3101	periódico	Wazny LD, Blake PG. Incompatibility of Vancomycin and Ceftazidime for Intraperitoneal Use. Perit Dial Int 2002 ; 22: 93-94.
3120	póster	Maillot-Pyszczek V, Bourdeaux D, Sautou V, Chopineau J. Etude de stabilité de solutions intravitréennes de vancomycine à 10 mg/ml. Congrès HOPIPHARM 2010
3122	periódico	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3125	periódico	Baker D S, Waldrop Bruce, Arnold John. Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. Int J Pharm Compound 2010 ; 14, 4: 346-349.
3201	periódico	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	periódico	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3327	periódico	LaPlante K.L, Woodmansee S, Mermel L.A. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. Am J Health-Syst Pharm 2012 ; 69:1405-1409
3365	periódico	Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. Y-Site Compatibility of Vancomycin and Piperacillin/Tazobactam at Commonly Utilized Pediatric Concentrations. Hosp Pharm 2013 ; 1: 44-47
3385	periódico	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	periódico	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.

3421	periódico	Leung E, Venkatesan N, Ly S.C, Scheetz M.H. Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions. Am J Health-Syst Pharm 2013 ;70:1163-1166.
3428	periódico	Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations. Hosp Pharm 2013 ; 48, 1: 44-47.
3485	periódico	Huey-Ping Ng, Kwong-Fah Koh, Lai-San Tham. Vancomycin causes dangerous precipitation when infused with gelatin fluid. Anaesthesia 2000 ; 55, 10: 1039-1040.
3523	Laboratorio	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3539	Laboratorio	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratorio	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3542	periódico	Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion Am J Health-Syst Pharm 2015 ; 72:390-395
3543	Laboratorio	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3548	Laboratorio	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3557	periódico	Chan A, Tawfik G, Cheng W. Physical Incompatibility between Parenteral Cloxacillin and Vancomycin. Can J Hosp Pharm 2013 ; 66, 5: 310-312
3564	Laboratorio	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	periódico	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3588	Laboratorio	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3662	Laboratorio	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3668	Laboratorio	Dexamethasone - Summary of Product Characteristics Hospira 2015
3728	periódico	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3767	periódico	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	póster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3813	periódico	Teibel H.M, Knoderer C.A, Nichols K.R. Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery. Hosp Pharm 2015 ; 50, 8: 710-713.

3824	periódico	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3841	periódico	Nicholas O?Donnell J, Venkatesan N, Manek M, Rhodes N.J, Scheetz M.H. Visual and absorbance analyses of admixtures containing vancomycin and piperacillin–tazobactam at commonly used concentrations. Am J Health-Syst Pharm 2016 ; 73:241-246
3883	Laboratorio	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3888	periódico	Ranganathan D, Naicker S,. Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). Perit Dial Int 2016 ; 36:421-426.
3948	periódico	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3951	periódico	Battistella M, Walker S, law S, Lok C. Antibiotic lock: In vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37°C Hemodial Int 2009 ; 13, 3: 322-328.
3956	periódico	Bastani B; Amin K; Herr A. Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique. ASAIO Journal 2005 ; 51,6:761-763.
3958	periódico	Henrickson K.J; . Powell K.R; . Schwartz C.L. A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities . J Infect Dis 1988 ; 157, 3: 600-601.
3960	periódico	Kufel W.D, Miller C.D, Johnson P.R, Reid K., Zahra J.J, Seabury R.W. Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story? Hosp Pharm 2017 ;52,2:132-137.
3964	periódico	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	periódico	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3984	periódico	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
3985	póster	Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M. Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro. Hopipharm Congress 2017 - Nancy 2017

3997	periódico	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4007	póster	Masse M, Genay S, Carta N, Delannoy-Rousseli?re C, Moreau F, Barthelemy C, Faure K, Decaudin B, Odou P. Etude de la stabilité de la vancomycine à 40 mg/ml au cours d'une perfusion de 24 heures. Hopipharm Congress 2017-Nancy 2017
4027	periódico	Wei Y, WonJoon Yang J, Boddu S, Jung R, Churchwell M. Compatibility, Stability, and Efficacy of Vancomycin Combined With Gentamicin or Ethanol in Sodium Citrate as a Catheter Lock Solution. Hosp Pharm 2017 ;52,10:685-690
4055	periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4089	periódico	Godet M, Simar J, Closset M, Hecq J.D, Braibant M, Soumoy L, Gillet P, Jamart J, Bihin B, Galanti L. Stability of Concentrated Solution of Vancomycin Hydrochloride in Syringes for Intensive Care Units. Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,1:23-30
4128	póster	Masse M, Genay S, Carta N, Moreau F, Delannoy-Rousselière C, Barthélémy C, Décaudin B, Faure K, Odou P. Stabilité de la vancomycine à des doses méningées dans les seringues au cours d'une perfusion de 24 heures. GRITA Symposium Perfusion 2017, Lille, France. 2017
4145	periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	periódico	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	periódico	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4348	periódico	D'Huart E, Vigneron J, Charmillon A, Clarot I, Demoré B. Physicochemical Stability of Vancomycin at High Concentrations in Polypropylene Syringes. Can J Hosp Pharm 2019 ;72(5):360-8
4354	póster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019
4373	periódico	Masse M, Genay S, Martin Mena A, Carta N, Lannoy D, Barthélémy C, Décaudin B, Odou P. Evaluation of the stability of vancomycin solutions at concentrations used in clinical services. EJHP 2020 ; 27(e1):e87-e92.
4380	Laboratorio	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4419	periódico	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434	periódico	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	periódico	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4470	periódico	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37

4488	periódico	Nezvalova-Henriksen K, Niklas Nilsson N, Tomine Østerberg C, Staven Berge V, Tho I. Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care. Pharmaceutics 2020 ; 12, 677.
4524	póster	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	periódico	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4569	periódico	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4603	periódico	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	periódico	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	póster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4655	periódico	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4698	periódico	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022 ; 7(1): 20220002
4742	periódico	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	periódico	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4842	periódico	Souha H Y, Alka G, Yunmei S, Nicole E W, Sanjay G. Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther 2024 ;18: 899–908.

4845	periódico	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4922	periódico	Wanandy T, Handley SA, Le TTA, Lau WY, Turner ME, Wiese MD. Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions. J Allergy Clin Immunol Pract 2024 13, 2: 343-352.
4924	periódico	Senarathna G, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang V, Batty K. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings EJHP 2023 2025;32:
4957	periódico	Send your ideas of compatibility studies to Stabilis®. Newsletter Stabilis 2025 69: 11.
5054	Laboratorio	POLTEOFİLİN 400 MG/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION - Summary of Product Characteristics. POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2018

Stabilis

Vancomycin hydrochloride



La estabilidad de las preparaciones farmacéuticas

3000mg Vancomycine	SyrSpend SF® >>60ml	2-8°C		90				3303
3750 mg ® = ?	SyrSpend SF PH4® >> 150 ml	2-8°C	?	90				4177
1250 mg ®=?	Orasweet® 25 ml Agua destilada 25 ml	23°C	?	26				3153
3000 mg Vancomycine Fresenius Kabi®	Oral Syrup® >> 60 ml	25°C		28				3794
1250 mg ®=?	Orasweet® 25 ml Agua destilada 25 ml	4°C		75				3153
3000 mg Vancomycine Fresenius Kabi®	Oral Syrup® >> 60 ml	4°C		91				3794
150 mg Vancomycine Fresenius Kabi®	Oral Syrup® >> 3 ml	25°C		28				3794
150 mg Vancomycine Fresenius Kabi®	Oral Syrup® >> 3 ml	4°C		91				3794

Bibliografía

	Tipo	Publicación
3153	periódico	Ensom M.H.H, Decarie D, Lakhani A. Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4°C and 25°C. Can J Hosp Pharm 2010 ; 63, 5: 366-372.
3303	periódico	Whaley P A, Voudrie M. Stability of Vancomycin in SyrSpend SF. Int J Pharm Compound 2012 ; 16, 2: 167-169.
3794	periódico	Smith A.D, Rempel G, Szeitz A, Klassen T.L, Ensom M.H.H. Vancomycin 50 mg/mL Suspension in Oral Syrup: Stability in Plastic Bottles and Syringes at 2 Temperatures. Can J Hosp Pharm 2017 ; 70,3 :247-249
4177	periódico	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526

Stabilis

Vancomycin hydrochloride



La estabilidad de las preparaciones farmacéuticas

25 mg	Vancomycine Dakota®	Glucosa al 5% >> 5 ml	-20°C		90			2649
500 mg	Vancocine®	NaCl 0.9% >> 10 ml	24-26°C		15			2732
500 mg	Vancocine®	NaCl 0.9% >> 10 ml	4°C		20			2732
30 mg	® = Mylan	Advanced Eye Relief® >> 3 mL	- 20 °C	?	14			4681
150 mg	® = Mylan	Advanced Eye Relief® >> 3 mL	- 20 °C	?	14			4681
500 mg	® = Pfizer	BSS solution® >> 10 mL	-20°C	?	90			4596
30 mg	® = Mylan	Advanced Eye Relief® >> 3 mL	2-8 °C	?	28			4681
150 mg	® = Mylan	Advanced Eye Relief® >> 3 mL	2-8 °C	?	28			4681
500 mg	® = Eli Lilly	BSS solution® >> 10 mL	24°C	±	28			4264
500 mg	® = Eli Lilly	BSS solution® >> 10 mL	4°C	±	28			4264
500 mg	® = Pfizer	BSS solution® >> 10 mL	5°C	?	30			4596

?		465 mg Vancocin®	Hidroxipropilmetilcelulosa 31.5 mg Dextran 70 10.5 mg Cloruro de benzalconio 1.05 mg Edetato de sodio 5.25 mg Agua para inyección >> 15 ml	-10°C		45			2420
?		465 mg Vancocin®	Hidroxipropilmetilcelulosa 31.5 mg Dextran 70 10.5 mg Cloruro de benzalconio 1.05 mg Edetato de sodio 5.25 mg Agua para inyección >> 15 ml	25°C		7			2420
?		465 mg Vancocin®	Hidroxipropilmetilcelulosa 31.5 mg Dextran 70 10.5 mg Cloruro de benzalconio 1.05 mg Edetato de sodio 5.25 mg Agua para inyección >> 15 ml	4°C		10			2420

Factores que influyen sobre la estabilidad

					2420

Bibliografía

	Tipo	Publicación
2420	periódico	Fuhrman LC, Jr, RT Stroman Stability of vancomycin in an extemporaneously compounded ophthalmic solution Am J Health-Syst Pharm 1998 ; 55: 1386-1388
2649	periódico	Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J. Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions. Int J Pharm 2002 ; 234, 1-2: 205-212.
2732	periódico	Barbault S, Aymard G, Feldman D, Pointereau-Bellanger A, Thuillier A. Stability of vancomycin eye drops. J Pharm Clin 1999 ; 18: 183-189.
4264	periódico	Karampatakis V, Papanikolaou T, Giannousis M, Goulas A, Mandraveli K, Kilmpasani M, Alexiou-Daniel S, Mirtsou-Fidani V. Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus. Acta Ophtalmol 2008
4596	periódico	Roura-Turet J, Rodriguez-Reyes M, Guerrero-Molina L, Soy-Muner D, López-Cabezas C. Stability of 5% vancomycin ophthalmic solution prepared using balanced salt solution after freezing for 90 days. Am J Health-Syst Pharm 2021 ;78,15:444–1447
4681	periódico	Chen P, Mar Z, Giannetti A, Hughes S, Gilbert J, Zhao F. An Exploratory Study of a New Vancomycin Eye Drops Formulation for Extemporaneous Compounding. Hosp Pharm 2022 ; 57, 1: 69-75.

Diccionario

	Antibiótico		Inyectables
	Nombre comercial		Estabilidad en solucion
	Envase		Molécula
	Concentración		Temperatura
	Conservación		Duración de la estabilidad
	biosimilar		datos contradictorios
	Bibliografía		Vidrio
	Agua para preparación inyectable		A cubierto de la luz
	Día		Cloruro de sodio 0,9%
?	No precisada		Hora
	Glucosa 5%		NaCl 0.9% + fenol 0.4%
PVC	Cloruro de polivinilo		Luz
P1 1.36	Dianéal® PD1 1.36% glucose (Baxter)	P1 3.86	Dianéal® PD1 3.86% glucose (Baxter)
EXTRANEAL	Extraneal® (Baxter)	PE	Polietileno
POF	Poliolefina	EVA	Etilén-vinil-acetato
	jeringa polipropileno	10	Glucosa 10%
15	Glucosa 15%	20	Glucosa 20%
25	Glucosa 25%	30	Glucosa 30%
PI	Elastómero de poliisopreno		Estabilidad en mezcla
	Solvente		Molécula
RL	Ringer lactato	0.45	Cloruro de sodio 0,45%
Ø	Ninguno	P2 4.25	Dianéal® PD2 4.25% Glucosa (Baxter)
P2 1.5	Dianéal® PD2 1.5% Glucosa (Baxter)	PP	Polipropileno
?	No precisado		Factores que influyen sobre la estabilidad
	Provoque		Degradación
	Precipitación		Compatibilidades
	Compatible		Incompatibilidad no especificada
	Incompatible		Precipitación inmediata
	Turbidez inmediata		Nutrición parenteral (con lípidos)
	Nutrición parenteral (libre de lípidos)		Turbidez en 4 horas

	Dianéal® 1.5% glucose (Baxter)		Dianéal® 2.5% glucose (Baxter)
	Dianéal® 4.25% glucose (Baxter)		Dianéal® PD1 4.25% Glucosa (Baxter)
	Dianéal® PD2 2.5% glucose (Baxter)		específico disolvente
	Cambio de color		Cambio de color después de 4 horas.
	Cambio de color después de 6 horas.		Normosol®
	Inestabilidad de la emulsión después de 6 ho		Precipitación después de 24 horas
	método de inyección		Perfusión intravenosa
	Perfusión continua		Intratecal
	Intraventricular		Intravítrea
	Subconjuntival		Bibliografía
	Solución Oral		La estabilidad de las preparaciones farmacéuticas
	Origine		Excipiente
	Botella de plástico		Polvo
	Frasco para medicamentos inyectables		Jeringa
	Gotas oculares		Con o sin luz
	Aumento		Diccionario